Clinical trials: Glucose
Diabetic Foot Ulcers
Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot Ulcers
A Multicenter, Prospective, Randomized Controlled Comparative Parallel Study To determine the safety and effectiveness of EpiCord as compared to standard of care (SOC) therapy for the treatment of chronic, non-healing diabetic…
- Trial name
- NCT02844660
- Testing
- EpiCord, Standard of Care
- Where
- 13 sites in United States
- Volunteers
- 130 people
- Sponsor
- MiMedx Group, Inc.
Diabetes, Diabetes Mellitus, Type 2
Initiation of Insulin Aspart in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.
- Trial name
- NCT00572806
- Testing
- insulin aspart
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
- Trial name
- NCT00306384
- Testing
- Alogliptin
- Where
- 114 sites in United States, Argentina and 10 more
- Volunteers
- 3,323 people
- Sponsor
- Takeda
Diabetes Mellitus, Type II
Bioequivalence Study for Acarbose / Metformin FDC
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).
- Trial name
- NCT01728740
- Testing
- Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Post-bariatric Hypoglycemia
An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia
The Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program.
- Trial name
- NCT07582874
- Testing
- Avexitide
- Where
- 4 sites in United States
- Sponsor
- Amylyx Pharmaceuticals Inc.
Diabetes Mellitus, Type 2
A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.
This study is intended to assess safety and tolerability of ASP1941 compared to placebo in adult subjects with type 2 diabetes mellitus
- Trial name
- NCT00790660
- Testing
- ASP1941
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
The study objectives are to assess over the gliclazide MR-SGLT2i combined treatment course in patients with T2DM adding SGLT2i to gliclazide MR-based therapy.
- Trial name
- ADD2DIA (NCT06708091)
- Where
- France
- Volunteers
- 537 people
- Sponsor
- Servier Affaires Médicales
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or…
- Trial name
- NCT01664247
- Testing
- insulin degludec, liraglutide
- Where
- 132 sites in United States, Canada and 9 more
- Volunteers
- 346 people
- Sponsor
- Novo Nordisk A/S
Type II Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to assess the efficacy of ASP1941 based on the changes in HbA1C as well as its safety in Asian subjects with type 2 diabetes mellitus.
- Trial name
- NCT01514838
- Testing
- ASP1941, acarbose
- Where
- 15 sites in South Korea, Taiwan
- Volunteers
- 46 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers
- Trial name
- NCT06492655
- Testing
- CKD-383(Fed), CKD-383(Fasted)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus.
- Trial name
- NCT00622089
- Testing
- DIO-902
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- DiObex
Type 1 Diabetes Mellitus
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes…
- Trial name
- NCT02688933
- Testing
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Where
- 100 sites in United States, Puerto Rico
- Volunteers
- 638 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate glycemic control on insulin defined as HbA1c ≥…
- Trial name
- NCT02582840
- Testing
- Dapagliflozin 5mg, Dapagliflozin 10mg
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
This is a two-centre, randomised, double-blind, double-dummy, 3-treatment, 3-period cross-over study using a standardised solid meal test in subjects with type 2 diabetes to investigate postprandial glucose control of…
- Trial name
- NCT02915250
- Testing
- BioChaperone® Combo, Humalog® Mix25, Humalog®
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 2
Renal Impairment in Type 2 Diabetic Subjects
The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with…
- Trial name
- NCT00554450
- Testing
- Dapagliflozin
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
Primary Objective: To compare the clinical efficacy of gemigliptin and vildagliptin as add-on therapy to metformin in terms of change in Hemoglobin A1c (HbA1c) reduction.
- Trial name
- NCT02343926
- Testing
- GEMIGLIPTIN LS15-0444, vildagliptin, metformin
- Where
- Russia
- Volunteers
- 443 people
- Sponsor
- Sanofi
Type 2 Diabetes
Dose Response Study in Japanese Patients
This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00261417
- Testing
- Tesaglitazar
- Where
- 20 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01849289)
- Testing
- Insulin Degludec, Insulin Glargine
- Where
- 81 sites in United States, Brazil and 5 more
- Volunteers
- 833 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT03338023
- Testing
- LY2963016, Lantus®, Insulin Lispro
- Where
- 20 sites in China
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
Please note this study is not being conducted in the United States. The purpose of this study is to assess the acute effects of vildagliptin, an unapproved drug, in reducing post-meal glucose levels by delaying gastric emptying.
- Trial name
- NCT00380380
- Testing
- Vildagliptin
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Novartis